Company intelligence / Profile preview

Vect-Horus

Marseille, Provence-Alpes-Côte d’Azur, Francevect-horus.com ↗
Ownership
Private
Employees
~40
Development stage
Phase 1
01

Overview

Vect-Horus has demonstrated proof-of-concept for its vectorization technology in animal models for various modalities. The company’s lead programs are advancing toward clinical trials with at least one theragnostic agent entering the clinic. The company has secured major licensing deals and research collaborations with global pharma partners including Novo Nordisk and Janssen Pharmaceuticals. Its technology has shown promise for improving drug delivery to the brain and tumors by overcoming biological barriers like the BBB.[4][8]

Therapeutic areas
OncologyPulmonologyCardiovascularOphthalmologyNeurology
Modalities
Small molecules (via vectorization)Oligonucleotides (siRNAs, ASOs, mRNAs)Antibodies (vectorized mAbs)Nanoparticles
Industry
Biotech
02

Drug pipeline

3 assets

Fc(A680)-VH4127

Preclinical

2 more assets in the full pipeline.

03

Partnerships

Novo Nordisk – exclusive global license agreement on VECTrans® platform for specified targets ($327M+ potential milestones plus royalties)[4].Janssen Pharmaceuticals / Johnson & Johnson – research collaboration on drug delivery to CNS/tumors[8].Sanofi – collaboration on neurodegenerative disease therapeutics using vectorization technology[7].Advanced Accelerator Applications (AAA) – partnership in molecular/nuclear imaging agents targeting tumors/CNS.[7]

Beyond the preview

Go deeper on Vect-Horus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vect-Horus.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call